Author: Tom Wilemon
Oct. 21, 2021—Vanderbilt-Ingram Cancer Center is leading an ambitious project to assess the impact of environmental exposures on cancer risk for people living in Southern states.
Oct. 14, 2021—Vanderbilt-Ingram Cancer Center is recruiting patients for a clinical trial using photoimmunotherapy for recurrent head and neck cancer.
Sep. 30, 2021—Vanderbilt-Ingram Cancer Center research is providing new insights into how genetic variants convey breast cancer susceptibility by altering the transcription factor proteins that convert DNA strands into RNA.
Sep. 24, 2021—The Meharry Medical College/Vanderbilt-Ingram Cancer Center/Tennessee State University Partnership has received renewed funding from the NCI to continue long-standing collaborations to eliminate cancer health disparities.
Sep. 23, 2021—Vanderbilt's Cathy Eng, MD, has been elected co-chair of the National Cancer Institute (NCI) Gastrointestinal Cancer Steering Committee.
Sep. 10, 2021—Vanderbilt research found that a novel immunotherapy demonstrated robust effectiveness in treating relapsed or refractory multiple myeloma.
Aug. 19, 2021—Ben Ho Park, MD, PhD, Cornelius Abernathy Professor of Medicine, has been named deputy director of Vanderbilt-Ingram Cancer Center (VICC).
Aug. 12, 2021—A biomarker that has proven to be a predictor for response to immunotherapies in melanoma patients also has clinical relevance for breast cancer patients, according to a new study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
Aug. 5, 2021—A new clinical trial seeks to determine whether immunotherapy in combination with short-course radiation followed by surgical resection could be a curative treatment for locally advanced rectal cancer.
Jul. 15, 2021—Kristen Ciombor, MD, MSCI, is one of 10 physicians nationwide selected by the National Cancer Institute (NCI) for the 2021 Cancer Clinical Investigator Team Leadership Award.
Jul. 15, 2021—Susan G. Komen has announced breast cancer research grants totaling $14 million, including funding for three separate initiatives led by Vanderbilt-Ingram Cancer Center (VICC) researchers.